Eledon Pharmaceuticals (NASDAQ: ELDN) presented 24-month follow-up data from its Phase 1b trial of tegoprubart in kidney transplant patients at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE